ONC
BeOne Medicines Ltd.Company with tickers: ONC, BEIGF
CIK
1651308
CUSIP
07725L102
Shares Outstanding
102,149,681
Price
Holdings
Short Volume
Short Interest
Fails to Deliver
SEC Filings
Earnings Calls
Insider Trading
Congress Trades
| Date | Insider | Role | Type | Shares |
|---|---|---|---|---|
| 2026-03-11 | Lee Chan Henry | SVP, General Counsel | Sell | 341 |
| 2026-03-11 | Lee Chan Henry | SVP, General Counsel | Other | 318,370 |
| 2026-03-11 | Lee Chan Henry | SVP, General Counsel | Convert | 1,430 |
| 2026-03-11 | Lee Chan Henry | SVP, General Counsel | Convert | 110 |
| 2026-03-06 | OYLER JOHN | Director, Chief Executive Officer | Other | 481,533 |
| 2026-03-06 | OYLER JOHN | Director, Chief Executive Officer | Award | 326,976 |
| 2026-03-06 | Lee Chan Henry | SVP, General Counsel | Award | 65,390 |
| 2026-03-06 | Wang Lai | President, Global Head of R&D | Other | 601,965 |
| 2026-03-06 | Wang Lai | President, Global Head of R&D | Other | 0 |
| 2026-03-06 | Wang Lai | President, Global Head of R&D | Award | 112,606 |
| 2026-03-06 | Wu Xiaobin | President and COO | Other | 12,365 |
| 2026-03-06 | Wu Xiaobin | President and COO | Award | 168,922 |
| 2026-03-06 | Rosenberg Aaron | Chief Financial Officer | Award | 79,014 |
| 2026-02-04 | Lee Chan Henry | SVP, General Counsel | Convert | 502 |
| 2026-02-04 | Lee Chan Henry | SVP, General Counsel | Sell | 664 |
| 2026-02-04 | Lee Chan Henry | SVP, General Counsel | Convert | 6,526 |
| 2026-02-04 | Lee Chan Henry | SVP, General Counsel | Other | 223,106 |
| 2026-01-07 | Lee Chan Henry | SVP, General Counsel | Other | 223,106 |
| 2026-01-07 | Lee Chan Henry | SVP, General Counsel | Convert | 2,626 |
| 2026-01-07 | Lee Chan Henry | SVP, General Counsel | Convert | 202 |
| 2026-01-07 | Lee Chan Henry | SVP, General Counsel | Sell | 664 |
| 2025-12-31 | Wang Lai | President, Global Head of R&D | Other | 0 |
| 2025-12-31 | Wang Lai | President, Global Head of R&D | Award | 427,895 |
| 2025-12-31 | Wang Lai | President, Global Head of R&D | Other | 601,965 |
| 2025-12-16 | OYLER JOHN | Director, Chief Executive Officer | Sell | 1,877 |
| 2025-12-15 | OYLER JOHN | Director, Chief Executive Officer | Sell | 1,791 |
| 2025-12-15 | OYLER JOHN | Director, Chief Executive Officer | Other | 5,141,041 |
| 2025-12-11 | Lee Chan Henry | SVP, General Counsel | Sell | 332 |
| 2025-12-11 | Lee Chan Henry | SVP, General Counsel | Convert | 1,313 |
| 2025-12-11 | Lee Chan Henry | SVP, General Counsel | Convert | 101 |
| 2025-12-10 | Lee Chan Henry | SVP, General Counsel | Convert | 1,313 |
| 2025-12-10 | Lee Chan Henry | SVP, General Counsel | Convert | 101 |
| 2025-12-10 | Lee Chan Henry | SVP, General Counsel | Sell | 332 |
| 2025-12-10 | Lee Chan Henry | SVP, General Counsel | Other | 223,106 |
| 2025-11-26 | Sanders Corazon (Corsee) D. | Director | Convert | 34,151 |
| 2025-11-26 | Sanders Corazon (Corsee) D. | Director | Other | 57,226 |
| 2025-11-26 | Sanders Corazon (Corsee) D. | Director | Convert | 2,627 |
| 2025-11-26 | Sanders Corazon (Corsee) D. | Director | Sell | 1,823 |
| 2025-11-17 | Wu Xiaobin | President and COO | Sell | 3,155 |
| 2025-11-17 | Wu Xiaobin | President and COO | Other | 968,978 |
| 2025-11-17 | Wu Xiaobin | President and COO | Other | 12,365 |
| 2025-11-13 | Wu Xiaobin | President and COO | Sell | 4,240 |
| 2025-11-12 | Wu Xiaobin | President and COO | Other | 1,020,861 |
| 2025-11-12 | Wu Xiaobin | President and COO | Sell | 500 |
| 2025-11-12 | Wu Xiaobin | President and COO | Other | 12,365 |
| 2025-11-12 | OYLER JOHN | Director, Chief Executive Officer | Gift | 858,533 |
| 2025-11-12 | Lee Chan Henry | SVP, General Counsel | Convert | 302 |
| 2025-11-12 | Lee Chan Henry | SVP, General Counsel | Other | 223,106 |
| 2025-11-12 | Lee Chan Henry | SVP, General Counsel | Sell | 664 |
| 2025-11-12 | Lee Chan Henry | SVP, General Counsel | Convert | 3,926 |
| 2025-11-11 | OYLER JOHN | Director, Chief Executive Officer | Other | 481,533 |
| 2025-11-11 | OYLER JOHN | Director, Chief Executive Officer | Gift | 151,320 |
| 2025-11-07 | Wang Xiaodong | Director | Gift | 424,073 |
| 2025-11-07 | Wang Xiaodong | Director | Other | 1,025,063 |
| 2025-10-08 | Lee Chan Henry | SVP, General Counsel | Convert | 302 |
| 2025-10-08 | Lee Chan Henry | SVP, General Counsel | Sell | 1,112 |
| 2025-10-08 | Lee Chan Henry | SVP, General Counsel | Convert | 3,926 |
| 2025-10-08 | Lee Chan Henry | SVP, General Counsel | Other | 223,106 |
| 2025-09-16 | OYLER JOHN | Director, Chief Executive Officer | Other | 7,450,894 |
| 2025-09-16 | OYLER JOHN | Director, Chief Executive Officer | Sell | 4,066 |
| 2025-09-10 | Lee Chan Henry | SVP, General Counsel | Other | 237,562 |
| 2025-09-10 | Lee Chan Henry | SVP, General Counsel | Convert | 6,802 |
| 2025-09-10 | Lee Chan Henry | SVP, General Counsel | Convert | 88,426 |
| 2025-09-10 | Lee Chan Henry | SVP, General Counsel | Sell | 1,112 |
| 2025-09-09 | Wang Lai | President, Global Head of R&D | Other | 1,023,529 |
| 2025-09-09 | Wang Lai | President, Global Head of R&D | Other | 0 |
| 2025-09-09 | Wang Lai | President, Global Head of R&D | Sell | 5,000 |
| 2025-09-09 | Wang Xiaodong | Director | Gift | 148,096 |
| 2025-09-09 | Wang Xiaodong | Director | Other | 1,025,063 |
| 2025-09-05 | Sanders Corazon (Corsee) D. | Director | Convert | 2,665 |
| 2025-09-05 | Sanders Corazon (Corsee) D. | Director | Convert | 34,645 |
| 2025-09-05 | Sanders Corazon (Corsee) D. | Director | Other | 57,226 |
| 2025-09-05 | Sanders Corazon (Corsee) D. | Director | Sell | 2,665 |
| 2025-09-02 | Ball Titus B. | Principal Accounting Officer | Other | 72,397 |
| 2025-09-02 | Ball Titus B. | Principal Accounting Officer | Sell | 122 |
| 2025-08-14 | Wu Xiaobin | President and COO | Sell | 400 |
| 2025-08-14 | Wu Xiaobin | President and COO | Convert | 30,756 |
| 2025-08-14 | Wu Xiaobin | President and COO | Convert | 399,828 |
| 2025-08-13 | Wu Xiaobin | President and COO | Sell | 8,900 |
| 2025-08-13 | Wu Xiaobin | President and COO | Other | 12,365 |
| 2025-08-13 | Wu Xiaobin | President and COO | Other | 1,228,328 |
| 2025-08-13 | Wu Xiaobin | President and COO | Convert | 22,773 |
| 2025-08-13 | Wu Xiaobin | President and COO | Convert | 296,049 |
| 2025-08-13 | Lee Chan Henry | SVP, General Counsel | Other | 252,018 |
| 2025-08-13 | Lee Chan Henry | SVP, General Counsel | Sell | 1,112 |
| 2025-08-13 | Lee Chan Henry | SVP, General Counsel | Convert | 4,381 |
| 2025-08-13 | Lee Chan Henry | SVP, General Counsel | Convert | 56,953 |
| 2025-08-01 | Rosenberg Aaron | Chief Financial Officer | Sell | 1,190 |
| 2025-08-01 | Rosenberg Aaron | Chief Financial Officer | Other | 215,332 |
| 2025-07-30 | Lee Chan Henry | SVP, General Counsel | Sell | 920 |
| 2025-07-30 | Lee Chan Henry | SVP, General Counsel | Other | 266,474 |
| 2025-07-30 | Wang Lai | President, Global Head of R&D | Sell | 259 |
| 2025-07-29 | Wang Lai | President, Global Head of R&D | Other | 0 |
| 2025-07-29 | Wang Lai | President, Global Head of R&D | Other | 1,023,529 |
| 2025-07-29 | Wang Lai | President, Global Head of R&D | Sell | 2,949 |
| 2025-07-18 | Wang Lai | President, Global Head of R&D | Other | 1,023,529 |
| 2025-07-18 | Wang Lai | President, Global Head of R&D | Sell | 700 |
| 2025-07-18 | Wang Lai | President, Global Head of R&D | Other | 0 |
| 2025-07-09 | OYLER JOHN | Director, Chief Executive Officer | Sell | 6,703 |
| 2025-07-09 | OYLER JOHN | Director, Chief Executive Officer | Other | 7,812,333 |